Professor, Family Medicine, Oakland University Wm Beaumont SOM
Neurology
Dr. R B. Sangal, MD
|
|
Give Review
R B. Sangal, MD practices Neurology. He graduated from SUNY Upstate Medical University. He has 3 awards "CMS Meaningful Use Stage 1 Certification", "Mark Hatfield Award for Public Policy" and "PQRS Certification". Sangal is a published doctor as well. He has 39 publications published. The latest was: Longer auditory and visual P300 latencies in patients with narcolepsy.
Publications
- Use of EEG Beta-1 Power and Theta/Beta Ratio Over Broca's Area to confirm Diagnosis of Attention Deficit/Hyperactivity Disorder in Children.
- Evaluating sleepiness-related Daytime function by querying wakefulness inability and fatigue: Sleepiness-Wakefulness Inability and Fatigue Test (SWIFT).
- Increased Central Adiposity in Morbidly Obese Patients with Obstructive Sleep Apnea.
- Cardiorespiratory fitness and obstructive Sleep apnea syndrome in morbidly obese patients.
- Effects of atomoxetine on growth in children with Attention-deficit/hyperactivity disorder following up to five years of treatment.
- Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
- Quality of life assessment in Adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
- A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with Attention-deficit/hyperactivity disorder.
- Patients with Attention-deficit/hyperactivity disorder without observed apneic episodes in sleep or daytime sleepiness have normal sleep on polysomnography.
- The clinical use of the MSLT and MWT.
- A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with Attention-deficit/hyperactivi...
- A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with Attention deficit hyperactivity disorder.
- What is a significant response in drug studies of Attention-deficit/hyperactivity disorder: statistical significance is necessary, but is it sufficient?
- Once-daily atomoxetine treatment for children and adolescents with Attention deficit hyperactivity disorder: a randomized, placebo-controlled study.
- Subjective and objective indices of Sleepiness (ESS and MWT) are not equally useful in patients with sleep apnea.
- Longer auditory and visual P300 latencies in patients with Narcolepsy.
- Conclusions from brain mapping: need for statistical rigor.
- P300 latency and age: a quadratic regression explains their relationship from age 5 to 85.
- Abnormal visual P300 latency in obstructive Sleep apnea does not change acutely upon treatment with CPAP.
- Measurement of P300 and sleep characteristics in patients with Hypersomnia: do P300 latencies, P300 amplitudes, and multiple sleep latency and maintenance of wakefulne...
- The indications for polysomnography and related procedures.
- Computerized scoring of abnormal human Sleep: a validation.
- Obstructive Sleep apnea and abnormal P300 latency topography.
- Prolonged P300 latency in Attention deficit hyperactivity disorder predicts poor response to imipramine.
- Closed head injury patients with Mild cognitive complaints without neurological or psychiatric findings have abnormal visual P300 latencies.
- Topography of auditory and visual P300 in normal children.
- Abnormal auditory P300 topography in Attention deficit disorder predicts poor response to pemoline.
- P300 latency: abnormal in sleep apnea with somnolence and Idiopathic hypersomnia, but normal in narcolepsy.
- Bilateral consequences of chronic unilateral deafferentation in the auditory system of the cricket Gryllus bimaculatus.
- Albuminuria and renal function in obese Adults evaluated for obstructive sleep apnea.
- Cardiorespiratory fitness and sleep-related breathing Disorders.
- Subjective and objective measures of sleep in children with Attention-deficit/hyperactivity disorder.
- When is Sleepiness a disease? How do we measure it?
- Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response.
- Attention-deficit/hyperactivity disorder: using P300 topography to choose optimal treatment.
- Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) amplitude predicts treatment response to atomoxetine.
- Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) topography predicts treatment response to methylphenidate.
- Rating scales for inattention and sleepiness are correlated in Adults with symptoms of sleep disordered breathing syndrome, but not in Adults with symptoms of attentio...
Schools
All India Institute Of Medical Sciences Aiims
SUNY Upstate Med Ctr Hosp
Johns Hopkins University Hospital
NihJohns Hopkins U
Delhi University
Procedures Preformed
- ADHD Testing
- Brainstem Auditory Evoked Response Test
- EEG (Electroencephalogram)
- Evaluation and Treatment of Sleep Disorders
- View All
Conditions Treated
- Adult Attention Deficit Disorder (ADD)
- Attention Deficit Disorder (ADD)
- Attention Deficit Hyperactivity Disorder (ADHD)
- Attention Problems
- View All
Doctors Specialties
- Clinical Neurophysiology
- Sleep Medicine
- Neurology
Accepted Insurances
- Aetna
- Blue Cross Blue Shield
- Cigna
- Cofinity
- Health Alliance
- Humana
- Special Needs Plan SNP
- MultiPlan
- Priority Health
- TriCare for Life
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Mark Hatfield Award for Public Policy
- PQRS Certification
Education
-
Johns Hopkins University -
SUNY Upstate Medical University -
All India Institute of Medical Sciences
Hospital
-
Beaumont Hospital - Royal Oak
Drug Facts
| NPI NUMBER | 1174618375 | |
| NPPES Provider LastName | SANGAL | |
| NPPES Provider FirstName | R | |
| NPPES Provider ZIPCode | 483141041 | |
| NPPES Provider State | MI | |
| Specialty Description | Neuropsychiatry | |
| Total Claim Count | 697.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1174618375 |
| Last Name Of The Provider | SANGAL |
| First Name Of The Provider | R |
| View All |
Similar Doctors
|
Dr. Bakulkumar M. Patel, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Muhammad A. Khan, MD |
|
|
Dr. Yevgeniy G. Stefadu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew R. Xavier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rizwan Qadir, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Paolo E. Di Liddo, DPM |
|
|
Jinal D. Shah, PT
This Doctor is OpenDoctor Recommended.
|